<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00722761</url>
  </required_header>
  <id_info>
    <org_study_id>2008-P-000754</org_study_id>
    <nct_id>NCT00722761</nct_id>
  </id_info>
  <brief_title>Safety and Efficacy Of Drospirenone and Ethinyl Estradiol vs Placebo in the Treatment of Truncal Acne</brief_title>
  <official_title>A Single-Center, Randomized Double-Blind, Parallel-Group Study to Examine the Safety and Efficacy Of YAZ Compared With Placebo In The Treatment Of Moderate Truncal Acne Vulgaris</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Massachusetts General Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Bayer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Massachusetts General Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to find out if taking a birth control pill, YAZ, is safe and
      effective for treating acne on the trunk (the main part of the body that does not include the
      arms, legs, and head).

      Acne vulgaris is a very common skin disorder. It is caused when oil-producing skin glands
      (sebaceous glands) become plugged. The plug can cause blackheads, whiteheads, pimples, and
      cysts on the face, neck, upper chest, and upper back.

      YAZ is a combination birth control pill. A &quot;combination&quot; pill means that it is made up of
      more than one major ingredient. Nearly all birth control pills are made up of a combination
      of estrogen and progestin hormones. Estrogens are steroid hormones produced by the ovaries
      responsible for the typical female features. Progestins are steroid hormones produced by the
      ovary and placenta responsible for making the uterus fit for pregnancy. YAZ also contains an
      estrogen called ethinyl estradiol, and a progestin called drospirenone. People who develop
      acne have sebaceous glands that are over-stimulated (that is, the sebaceous glands have
      increased activity) by male sex hormones (androgens). The progestin in YAZ blocks the male
      sex hormones (androgens) that cause acne.

      The study drug being used in this study is called YAZ. It has been approved by the U.S. Food
      and Drug Administration (FDA) to treat moderate acne in women who want an oral contraceptive
      for birth control.

      In this study, YAZ will be compared to a placebo for safety and effectiveness. A placebo
      looks like the study drug but contains no active drug (like a sugar pill). We use placebos in
      research studies to learn if the effects seen in research subjects are truly from the study
      drug or from other reasons.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Acne is a common skin disease that affects 85-100% of the population. Although it often
      appears during puberty, it may persist during the third decade of life and even later. It is
      characterized by a variety of lesions consisting of non-inflammatory lesions known as
      comedones, and inflammatory lesions such as papules, pustules, nodules and cysts. It commonly
      occurs on the face, chest, and back. Although not as noticeable as facial acne, truncal acne
      may also affect a person's self esteem and body image and reduce one's participation in
      sports because of the need to undress in a shared locker room. Most acne studies focus on
      facial acne and ignore treatment outcomes in the chest and back.

      The pathogenesis of acne is multifactorial, developing in the sebaceous gland. These factors
      include intrafollicular hypercornification, which induces follicular obstruction resulting in
      comedone formation, excess sebum production, Propionibacterium acnes activity and
      inflammation.

      Hormone therapies, such as oral contraceptives and antiandrogens (e.g. spironolactone)
      counteract the effects of androgens on the sebaceous glands. It has been over ten years since
      estrogen-containing oral contraceptives (OCs) first obtained FDA approval for use in acne.
      Since then, several randomized controlled trials have corroborated their efficacy and safety
      for this growing indication in women of child bearing age. Studies have shown hormonal
      therapies to be effective in treating moderate acne vulgaris in women with no known
      contraindication to OC therapy.

      YAZ is an oral contraceptive that is FDA approved for acne vulgaris. Unlike other progestins,
      drospirenone has unique antimineralocorticoid (mild diuretic effect) and antiandrogenic
      properties. The antiandrogenic property of drospirenone means that it blocks the male sex
      hormones that can cause acne. In two multicenter, double blind, randomized,
      placebo-controlled studies, 889 subjects, ages 14 to 45 years, with moderate acne received
      YAZ or placebo for six 28 day cycles. The primary efficacy endpoints were the percent change
      in inflammatory lesions, non-inflammatory lesions, total lesions, and the percentage of
      subjects with a &quot;clear&quot; or &quot;almost clear&quot; rating on the Investigator's Static Global
      Assessment (ISGA) scale on day 15 of cycle 6.

      Subjects will be assigned to a treatment group upon randomization. Bayer HealthCare
      Pharmaceuticals personnel, investigators, subjects and study nurse/coordinators will be
      blinded to the study product treatment assignment. The study duration will be 24 weeks with
      visits at screening, baseline (week 0), week 6, week 12, week 18, and week 24. Lesion counts
      (total, inflammatory, non-inflammatory) and an ISGA, and photography will be performed on
      every visit. A physical examination will be done at baseline and Week 24. Safety will be
      assessed from reported adverse events (AEs).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2009</start_date>
  <completion_date type="Actual">April 2012</completion_date>
  <primary_completion_date type="Actual">April 2012</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent Change in Truncal Lesion Counts</measure>
    <time_frame>0-24 weeks</time_frame>
    <description>Acne lesion count (noninflammatory, inflammatory and total lesions) difference between week 0 (baseline) and week 24 is divided by the acne lesion count at week 0 and multiplied by 100. A positive change indicates a decrease in truncal acne lesions.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of Subjects Rated Clear or Almost Clear on the IGA and SGA at Week 24/ Early Termination</measure>
    <time_frame>24 weeks</time_frame>
    <description>Percentage of subjects rated Clear (score 0) or Almost Clear (score 1) on the Investigator's Global Assessment (IGA) of truncal acne at Week 24 as well as Subject's Assessment of Acne at Week 24/Early Termination were taken. It was computed by: number of successes (those scored 0 or 1)divided by the number of participants multiplied by 100.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">30</enrollment>
  <condition>Acne Vulgaris</condition>
  <arm_group>
    <arm_group_label>Drosperinone and Ethinyl estradiol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Drospirenone and Ethinyl estradiol (3mg/0.02mg)(YAZ)tablet once a day</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo tablet</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo tablet once a day</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>drospirenone and ethinyl estradiol</intervention_name>
    <description>Drosperinone (3mg) and ethinyl estradiol (0.02mg) tablet given once daily for 24 weeks</description>
    <arm_group_label>Drosperinone and Ethinyl estradiol</arm_group_label>
    <other_name>YAZ</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo tablet</intervention_name>
    <description>Placebo tablet (no active drug) given once daily for 24 weeks</description>
    <arm_group_label>Placebo tablet</arm_group_label>
    <other_name>Placebo</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Female Subjects 18-45 years of age who have achieved spontaneous menarche.

          -  A clinical diagnosis of truncal acne vulgaris and the desire for an oral contraceptive
             for birth control.

          -  A minimum of 10 but not more than 50 inflammatory lesions on the back and chest
             combined.

          -  Maximum of 5 nodules.

          -  Willing and able to understand and sign informed consent.

          -  Able to complete study and comply with study procedures.

        Exclusion Criteria:

          -  Use of topical acne medications such as tretinoin, benzoyl peroxide or topical
             antibiotics within 2 weeks

          -  Use of oral antibiotics within 30 days.

          -  Use of systemic corticosteroids within 4 weeks.

          -  Use of oral contraceptives within 12 weeks.

          -  Use of isotretinoin in past six months.

          -  Use of phototherapy devices for acne such as ClearLight or Zenozapper within 1 week.

          -  Use of tanning booths or lamps within 1 week prior to baseline.

          -  BMI &gt;30

          -  History of renal insufficiency

          -  History of hepatic dysfunction

          -  History of adrenal Insufficiency

          -  History of vascular or metabolic disease including existing or previous arterial
             thromboembolic diseases (myocardial infarction, stroke), existing or previous venous
             thromboembolic diseases (deep vein thrombosis, pulmonary embolism), and any condition
             which could increase the risk to suffer any of the above mentioned disorders

          -  History of hypertension

          -  Diabetes mellitus with vascular involvement

          -  Migraine headaches with focal neurological symptoms

          -  Recent major surgery with prolonged immobilization

          -  Known or suspected carcinoma of the breast

          -  Carcinoma of the endometrium or other known or suspected estrogen-dependent neoplasia

          -  Undiagnosed abnormal genital bleeding

          -  Cholestatic jaundice of pregnancy or jaundice with prior pill use

          -  Liver tumor (benign or malignant) or active liver disease

          -  Smoking &gt; Â½ pack of cigarettes/week

          -  Regular intake of medications that may increase potassium levels such as NSAIDS,
             potassium sparing diuretics, potassium supplementation, ACE inhibitors, Angiotensin-II
             receptor antagonists, heparin and aldosterone antagonists.

          -  Hypersensitivity to any component of the study drug

          -  Clinically significant abnormal findings or conditions (other than acne), which might,
             in the opinion of the Principal Investigator, interfere with study evaluations or pose
             a risk to subject safety during the study.

          -  Subjects who are known to be pregnant or planning a pregnancy.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>45 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alexandra B. Kimball, MD, MPH</last_name>
    <role>Principal Investigator</role>
    <affiliation>Massachusetts General Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Clinical Unit for Research Trials in Skin</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.harvardskinstudies.org/</url>
    <description>Click here for more studies.</description>
  </link>
  <verification_date>January 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>July 24, 2008</study_first_submitted>
  <study_first_submitted_qc>July 25, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">July 28, 2008</study_first_posted>
  <results_first_submitted>December 17, 2012</results_first_submitted>
  <results_first_submitted_qc>January 29, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">March 5, 2013</results_first_posted>
  <last_update_submitted>January 29, 2013</last_update_submitted>
  <last_update_submitted_qc>January 29, 2013</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 5, 2013</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Massachusetts General Hospital</investigator_affiliation>
    <investigator_full_name>Alexandra Kimball</investigator_full_name>
    <investigator_title>Director, Clinical Unit for Research Trials in Skin</investigator_title>
  </responsible_party>
  <keyword>YAZ</keyword>
  <keyword>oral contraceptive</keyword>
  <keyword>Acne vulgaris</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acne Vulgaris</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Estradiol</mesh_term>
    <mesh_term>Polyestradiol phosphate</mesh_term>
    <mesh_term>Ethinyl Estradiol</mesh_term>
    <mesh_term>Drospirenone</mesh_term>
    <mesh_term>Estradiol 3-benzoate</mesh_term>
    <mesh_term>Estradiol 17 beta-cypionate</mesh_term>
    <mesh_term>Estradiol valerate</mesh_term>
    <mesh_term>Drospirenone and ethinyl estradiol combination</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>Females, age 18 to 45 years, who achieved spontaneous menarche and had a diagnosis of truncal acne of 10 to 50 inflammatory lesions on the back and chest combined with not more than 5 nodules</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Drosperinone and Ethinyl Estradiol</title>
          <description>Drospirenone (3mg) and Ethinyl estradiol (0.02mg) (YAZ)tablet once a day</description>
        </group>
        <group group_id="P2">
          <title>Placebo Tablet</title>
          <description>Placebo tablet once a day</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="14"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED AT LEAST 1 FOLLOW-UP VISIT</title>
              <participants_list>
                <participants group_id="P1" count="15"/>
                <participants group_id="P2" count="10"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="10"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="6"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="4"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Withdrawal by Subject</title>
              <participants_list>
                <participants group_id="P1" count="5"/>
                <participants group_id="P2" count="2"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Drosperinone and Ethinyl Estradiol</title>
          <description>Drospirenone (3mg) and Ethinyl estradiol (0.02mg) (YAZ)tablet once a day</description>
        </group>
        <group group_id="B2">
          <title>Placebo Tablet</title>
          <description>Placebo tablet once a day</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="16"/>
            <count group_id="B2" value="14"/>
            <count group_id="B3" value="30"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23" spread="5.1"/>
                    <measurement group_id="B2" value="24" spread="3.7"/>
                    <measurement group_id="B3" value="24" spread="4.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="30"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Hispanic or Latino</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>African American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Caucasian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMI</title>
          <units>kg/m2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="23.2" spread="2.2"/>
                    <measurement group_id="B2" value="23.6" spread="2.6"/>
                    <measurement group_id="B3" value="23.4" spread="2.9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Percent Change in Truncal Lesion Counts</title>
        <description>Acne lesion count (noninflammatory, inflammatory and total lesions) difference between week 0 (baseline) and week 24 is divided by the acne lesion count at week 0 and multiplied by 100. A positive change indicates a decrease in truncal acne lesions.</description>
        <time_frame>0-24 weeks</time_frame>
        <population>Intention to treat analysis. Only participants with at least one follow up were included in the analysis. Last observation carried forward was used to fill up missing data.</population>
        <group_list>
          <group group_id="O1">
            <title>Drosperinone and Ethinyl Estradiol</title>
            <description>Drospirenone (3mg) and Ethinyl estradiol (0.02mg) (YAZ)tablet once a day</description>
          </group>
          <group group_id="O2">
            <title>Placebo Tablet</title>
            <description>Placebo tablet once a day</description>
          </group>
        </group_list>
        <measure>
          <title>Percent Change in Truncal Lesion Counts</title>
          <description>Acne lesion count (noninflammatory, inflammatory and total lesions) difference between week 0 (baseline) and week 24 is divided by the acne lesion count at week 0 and multiplied by 100. A positive change indicates a decrease in truncal acne lesions.</description>
          <population>Intention to treat analysis. Only participants with at least one follow up were included in the analysis. Last observation carried forward was used to fill up missing data.</population>
          <units>percentage change of lesions</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Noninflammatory lesions</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="52.1" spread="43.3"/>
                    <measurement group_id="O2" value="-9.2" spread="77.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Inflammatory lesions</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.2" spread="40.9"/>
                    <measurement group_id="O2" value="18.2" spread="40.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Total acne lesions</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="51.8" spread="31.9"/>
                    <measurement group_id="O2" value="17" spread="47.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Subjects Rated Clear or Almost Clear on the IGA and SGA at Week 24/ Early Termination</title>
        <description>Percentage of subjects rated Clear (score 0) or Almost Clear (score 1) on the Investigator's Global Assessment (IGA) of truncal acne at Week 24 as well as Subject's Assessment of Acne at Week 24/Early Termination were taken. It was computed by: number of successes (those scored 0 or 1)divided by the number of participants multiplied by 100.</description>
        <time_frame>24 weeks</time_frame>
        <population>Intention to treat analysis. Participants with at least one follow up visit were included in the analysis. Last observation carried forward was used to fill up missing values/</population>
        <group_list>
          <group group_id="O1">
            <title>Drosperinone and Ethinyl Estradiol</title>
            <description>Drospirenone (3mg) and Ethinyl estradiol (0.02mg) (YAZ)tablet once a day</description>
          </group>
          <group group_id="O2">
            <title>Placebo Tablet</title>
            <description>Placebo tablet once a day</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects Rated Clear or Almost Clear on the IGA and SGA at Week 24/ Early Termination</title>
          <description>Percentage of subjects rated Clear (score 0) or Almost Clear (score 1) on the Investigator's Global Assessment (IGA) of truncal acne at Week 24 as well as Subject's Assessment of Acne at Week 24/Early Termination were taken. It was computed by: number of successes (those scored 0 or 1)divided by the number of participants multiplied by 100.</description>
          <population>Intention to treat analysis. Participants with at least one follow up visit were included in the analysis. Last observation carried forward was used to fill up missing values/</population>
          <units>percentage of participants</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="15"/>
                <count group_id="O2" value="10"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Investigator Global Assessment IGA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="53.3"/>
                    <measurement group_id="O2" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Subject Assessment SGA</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="60"/>
                    <measurement group_id="O2" value="80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Drosperinone and Ethinyl Estradiol</title>
          <description>Drospirenone (3mg) and Ethinyl estradiol (0.02mg) (YAZ)tablet once a day</description>
        </group>
        <group group_id="E2">
          <title>Placebo Tablet</title>
          <description>Placebo tablet once a day</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>1</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>Loss of appetite</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
              <event>
                <sub_title>moodiness</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>break through bleeding</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="16"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="14"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Early termination leading to small number of subjects analyzed</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Alexa B. Kimball</name_or_title>
      <organization>MGH Curtis</organization>
      <phone>617-726-5066</phone>
      <email>harvardskinstudies@partners.org</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

